How the once-dominant cancer company has overhauled its strategy for long-term growth

Eleven label expansions also among committee’s November recommendations

As data on amyloid-targeting drugs have emerged, pressing questions—and answers—about their leading safety concern have come into focus

Companies, academics, advocates push back on claims they should have disclosed genotype to Alzheimer's trial participants

Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex

Plus: FDA & the election and state of play for China biotech 

While the Phase II data at CTAD cast doubt on UCB’s bepranemab, they represent a critical advance for the field

Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more

Together, blood-brain barrier transport technology and Phase I Alzheimer’s therapy drive rare 10-figure early-stage takeout